Chester County News and Community Website
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has revealed new preclinical findings and a clinical update on APR-1051, an innovative oral WEE1 inhibitor being studied for the treatment of …
Aprea Therapeutics Announces Promising Data on APR-1051 for HPV-Positive Cancers Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a key milestone in its ACESOT-1051 clinical trial, as the first patient with HPV-positive (HPV+) head and neck squamous cell carcinoma (HNSCC) …
Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company, shared its financial results for 2024 and provided a progress update on its lead programs aimed at advancing cancer …
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center to advance preclinical studies of its WEE1 kinase inhibitor, APR-1051. …
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced significant advancements in its intellectual property portfolio, reinforcing the company’s leadership in the development of DNA Damage Response (DDR) therapeutics for …
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation Read More